Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Becton, Dickinson & Co. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Becton, Dickinson & Co. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
The analysis of the quarterly financial metrics reveals several notable trends in profitability and efficiency over the observed periods.
- Gross Profit Margin
- The gross profit margin shows a generally declining trend from approximately 48.6% at the end of 2016 to around 45.8% by early 2022. There are minor fluctuations along the way, with the margin reaching a low point in mid-2020 near 44.3%. This decrease indicates a gradual reduction in the company’s ability to maintain its production costs relative to revenue over the years.
- Operating Profit Margin
- The operating profit margin exhibits significant volatility across the quarters. Initially high in late 2016 at 15.2%, it fell sharply in mid-2017 reaching as low as roughly 4.7% during the first quarter of 2018. Although moderate recovery is observed afterwards—with margins stabilizing mostly between 7.9% and 13.8%—the fluctuation suggests challenges in controlling operating expenses or variations in operational efficiency. Notably, improvements are evident from late 2020 onward, reaching near 13% by early 2022.
- Net Profit Margin
- The net profit margin mirrors the variability found in operating profit. Starting at about 10.5% at the end of 2016, it dips substantially in early 2018 to a low around 0.3%. Subsequent data indicates a recovery trend with margins rising steadily to above 9% by late 2021. This pattern reflects the company’s fluctuating bottom-line profitability, with a clear improvement in recent quarters.
- Return on Equity (ROE)
- The return on equity shows a sharp decline from over 17% at the end of 2016 to below 2% in early 2018. After this trough, ROE gradually increases, reaching levels near 8.8% by late 2021, before slightly dipping in early 2022. This trend illustrates a period of diminished investor returns followed by a slow but consistent recovery in shareholder value generation.
- Return on Assets (ROA)
- The return on assets follows a similar trajectory as ROE but at lower absolute percentages. Starting slightly above 5% in late 2016, it plunges below 1% in early 2018. Later, ROA slowly increases to nearly 3.9% by late 2021, before a minor decline in early 2022. This indicates that asset efficiency dropped noticeably but has been improving gradually over the recent years.
Overall, the data reflects a period of financial challenges beginning around late 2017 through early 2018, affecting profitability and efficiency ratios substantially. However, a gradual recovery trend is observable through most metrics since 2019, with stabilization and improvements in profitability margins and returns by the end of the observed period. This suggests enhanced operational performance and financial management in the latter years.
Return on Sales
Return on Investment
Gross Profit Margin
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Q2 2022 Calculation
Gross profit margin = 100
× (Gross profitQ2 2022
+ Gross profitQ1 2022
+ Gross profitQ4 2021
+ Gross profitQ3 2021)
÷ (RevenuesQ2 2022
+ RevenuesQ1 2022
+ RevenuesQ4 2021
+ RevenuesQ3 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenues exhibited an overall increasing trend from the end of 2016 through early 2022. Starting around 2,922 million USD, there was a substantial rise observed in early 2018, reaching above 4,000 million USD. This upward trajectory continued with revenues peaking above 5,300 million USD at the beginning of 2021. Some fluctuations occurred, especially around the end of 2019 to mid-2020, likely indicating periodic volatility or external influences affecting sales.
- Gross Profit Trends
- Gross profit showed a generally positive growth pattern over the observed period. Initial figures near 1,452 million USD increased to peak levels of over 2,700 million USD by late 2020. Despite some short-term declines, particularly around mid-2020, the gross profit rebounded significantly, ending the period notably higher than at the start.
- Gross Profit Margin Analysis
- The gross profit margin displayed moderate variability throughout the quarters. Early margins hovered around 48.5%, with a marked decrease in early 2018 dropping to approximately 45%. Subsequently, margins stabilized in the mid-40% range, fluctuating between about 44% and 47%. This pattern suggests some pressure on cost management or pricing strategies during periods of higher revenues, as margins declined when absolute gross profit and revenue figures were growing considerably.
- Overall Observations
- The data reflects a scenario of growing scale combined with margin compression. Revenues and gross profit both increased significantly across the period, indicating successful sales expansion or enhanced market penetration. However, the decrease and stabilization at slightly lower gross profit margins imply either rising costs or competitive pricing pressures. Noteworthy is the resilience shown in recovering gross profit after dips, affirming effective adaptation to changing business conditions.
Operating Profit Margin
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Operating income (loss) | |||||||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Q2 2022 Calculation
Operating profit margin = 100
× (Operating income (loss)Q2 2022
+ Operating income (loss)Q1 2022
+ Operating income (loss)Q4 2021
+ Operating income (loss)Q3 2021)
÷ (RevenuesQ2 2022
+ RevenuesQ1 2022
+ RevenuesQ4 2021
+ RevenuesQ3 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Operating Income (Loss)
- Over the analyzed periods, the operating income exhibited significant volatility. The initial quarters show a wide range, with some quarters marked by negative values (notably in mid-2017), indicating operational challenges during those times. However, a recovery trend is observed from late 2017 onwards, with operating income mostly returning to positive territory and demonstrating an upward trend peaking at the end of 2020 with a pronounced spike. Despite fluctuations, the overall pattern suggests a resilience and capacity for recovery after setbacks.
- Revenues
- Revenue figures reveal a general upwards trend despite some fluctuations. The values increased from the end of 2016 through to early 2019 with gradual growth, reaching a peak near the end of 2020 and early 2021. While some quarters show minor declines, the revenue remains relatively stable with a tendency to increase, suggesting overall growth in sales or service provision. This steady revenue growth likely provided a supportive foundation for operational performance despite periodic operational income volatility.
- Operating Profit Margin
- The operating profit margin percentage displays variability corresponding to the fluctuations in operating income. Margins were relatively strong at the start of the period but experienced a notable decline during 2017, aligning with the negative operating income reported in mid-2017. Subsequent quarters show margins stabilizing and improving, maintaining a more consistent performance typically ranging from about 8% to 13%. The margin peaks notably towards the end of 2020 and remains relatively robust through 2021 and early 2022, indicating improved profitability relative to revenue.
- Summary of Trends
- The data presents a company experiencing periods of operational difficulty, especially around mid-2017, as reflected by negative operating income and depressed profit margins. Nevertheless, these challenges were followed by recovery phases marked by increasing operating income and improved margins. Revenue generally trended upwards, indicating underlying business growth. The fluctuations in profitability margins correspond closely with the operating income movements, suggesting effective cost management struggles in certain quarters but overall strengthening profitability over time. The last reported quarters reflect improved financial health and stability.
Net Profit Margin
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Q2 2022 Calculation
Net profit margin = 100
× (Net income (loss)Q2 2022
+ Net income (loss)Q1 2022
+ Net income (loss)Q4 2021
+ Net income (loss)Q3 2021)
÷ (RevenuesQ2 2022
+ RevenuesQ1 2022
+ RevenuesQ4 2021
+ RevenuesQ3 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income (Loss) Trends
- Net income exhibits notable volatility throughout the periods analyzed. The company experienced several quarters with negative net income early in the series, specifically in the first three quarters of 2017. Subsequently, profitability fluctuated with some quarters showing strong positive net income, peaking in the first quarter of 2021 with over 1 billion US dollars. Despite fluctuations, there is an overall trend towards positive and increasing net income in the later periods, indicating improved profitability.
- Revenues Over Time
- Revenues demonstrated a general upward trend from the end of 2016 through the first quarter of 2022, rising from approximately 2.9 billion US dollars to around 5 billion US dollars. There were fluctuations within this timeframe, with occasional slight decreases observed, such as between the fourth quarter of 2018 and mid-2020. However, the overall growth in revenues suggests expansion in the company's operations or sales volume.
- Net Profit Margin Analysis
- The net profit margin showed substantial variability across quarters. Initially, margins were relatively moderate, with occasional dips below 1%, particularly in early 2018. A significant recovery observed afterward saw margins largely stabilize and improve, especially from 2020 onwards, with peaks over 10% in late 2020 and 2021. This improvement in net profit margin aligns with the increasing net income levels and suggests better cost control or enhanced pricing power.
- Insights
- The company’s financial performance is characterized by initial instability in profitability, which transitions to a more robust and consistent profit generation phase. The steady revenue growth paired with improving profit margins indicates strengthening operational efficiency and market presence. Nevertheless, the fluctuations early in the period warrant attention to potential risks or external factors impacting earnings during those quarters.
Return on Equity (ROE)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Q2 2022 Calculation
ROE = 100
× (Net income (loss)Q2 2022
+ Net income (loss)Q1 2022
+ Net income (loss)Q4 2021
+ Net income (loss)Q3 2021)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income (Loss)
- The net income exhibits notable volatility throughout the periods analyzed. Initial quarters show positive net income figures, with a peak of 599 million US dollars in December 2017. However, there are intermittent losses or declines, such as the negative results in June 2017 (-132 million) and March 2018 (-12 million). From 2019 onward, net income generally trends upward, culminating in a significant increase in December 2020 (1,003 million). Although subsequent quarters fluctuate, net income remains relatively strong compared to earlier periods, finishing at 454 million in March 2022.
- Shareholders’ Equity
- Shareholders’ equity shows a steady upward trend overall. Starting from 7,583 million US dollars at the end of 2016, equity grows appreciably, more than doubling by December 2017, reaching 21,247 million. After this increase, equity levels remain relatively stable, oscillating slightly around the 21,000 to 24,000 million range. By March 2022, equity attains approximately 24,525 million, indicating consistent capital retention and growth over the period.
- Return on Equity (ROE)
- ROE experiences fluctuations corresponding to variations in net income, ranging from a high of 17.26% in December 2016 to a low of 0.22% in March 2018. Periods of decreased profitability reflect in lower ROE values, particularly notable in early 2018 and parts of 2020. However, from late 2020 through 2021, there is an observable upward trend in ROE, peaking at 8.84% in September 2021 before slightly decreasing to 7.83% by March 2022. This pattern suggests improved efficiency in generating returns on shareholders' equity in recent periods.
Return on Assets (ROA)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Q2 2022 Calculation
ROA = 100
× (Net income (loss)Q2 2022
+ Net income (loss)Q1 2022
+ Net income (loss)Q4 2021
+ Net income (loss)Q3 2021)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The quarterly financial data reveals several noteworthy trends across the reported periods.
- Net Income (Loss)
- The net income demonstrates significant volatility over the quarters. Initial quarters show fluctuating profits with occasional losses, such as during mid-2017. After a period of relatively low or negative net income in late 2017 and early 2018, profitability improved substantially from mid-2018 onwards. Of particular note are marked spikes in net income around late 2020 and early 2021, reaching peak values notably higher than earlier periods. Despite some fluctuations toward late 2021 and early 2022, the overall trajectory from 2018 to 2022 suggests strengthened profitability.
- Total Assets
- Total assets exhibit a generally stable to slightly increasing trend, with some notable jumps. A significant increase is visible from early 2017 to the end of 2017, more than doubling from roughly 24 billion to over 55 billion US dollars, followed by consistent values in the range of 50 to 55 billion for subsequent quarters. From 2019 onward, total assets remain relatively steady, fluctuating mildly but maintaining a sustained elevated level compared to earlier years.
- Return on Assets (ROA)
- The ROA percentage fluctuates considerably throughout the period. Earlier quarters reveal relatively higher ROA at approximately 5%, declining markedly by late 2017 and early 2018. Post-2018, ROA values generally remain between 1% and 3%, with gradual improvements spotted after 2019. Notably, an ascending trend in ROA is observed from late 2020 through 2021, peaking near 3.88% before showing a slight dip. These trends reflect the fluctuations in profitability relative to asset base and an improvement in asset efficiency during the latter half of the period.
In summary, the company exhibits a volatile net income pattern with significant improvements in profitability starting mid-2018. Total assets have increased significantly during the earlier part of the timeframe and then stabilized at a higher base. ROA trends mirror the profitability developments, showing an initial decline but subsequent recovery and moderate growth, indicating enhanced utilization of assets in recent years.